Tegafur/Gimeracil/Oteracil Potassium

Tier C — Watch / trade

Taiho Pharmaceutical Co., Ltd.

Originator

1999

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：TYMS

Brand：Teggio, TS-1, Tigio, Teysuno

Indications (approved)：Gastric cancer, Bile duct cancer, Non-small cell lung cancer, Colorectal cancer, Breast cancer, Head and neck cancer, Pancreatic cancer

Regional status

No progress

2006-02-01

Approved

2011-03-14

China

Approved

2008-12-19

Japan

Approved

1999-01-25

Factories producing this API9

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

9 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Tegafur/Gimeracil/Oteracil Potassium?

Approved indications include: Gastric cancer, Bile duct cancer, Non-small cell lung cancer, Colorectal cancer, Breast cancer, Head and neck cancer, Pancreatic cancer.

When does the Tegafur/Gimeracil/Oteracil Potassium patent expire?

No public expiry year is available for Tegafur/Gimeracil/Oteracil Potassium yet; this page updates once verified.

How do I get a quote for Tegafur/Gimeracil/Oteracil Potassium intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27